Why TG Therapeutics Inc. Shares Jumped

TG Therapeutics shares jump after announcing a licensing deal. Find out if this deal makes as much sense as today's pop would imply.

Jun 24, 2014 at 4:01PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of TG Therapeutics (NASDAQ:TGTX), a clinical-stage biopharmaceutical company focused on developing therapies to treat cancer and other unmet disease areas, surged as much as 19% after announcing a global licensing agreement with Ligand Pharmaceuticals (NASDAQ:LGND).

So what: Under the terms of the deal, TG Therapeutics is licensing the global rights to Ligand's IRAK4 inhibitor research program. Specifically, IRAK4 is a "key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in patients with Waldenstrom's Macroglobulinemia, a rare B-cell cancer, as well as a sub-set of patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia." As noted, IRAK4 inhibition could also provide benefits to other autoimmune disorders.

In exchange for licensing rights to this currently preclinical program TG Therapeutics will give Ligand an upfront licensing fee of 125,000 unregistered common stage of TG stock. TG will also pay Ligand development and sales-based milestones, as well as a mid-to-high single-digit royalty on net sales should any therapies be approved.

Now what: I believe this is a necessary move for TG Therapeutics which needs to find a way to expand its pipeline and give itself more chances to "hit a home run." Currently, it only has three clinical studies under way – although TG-1101 as a late-stage treatment for chronic lymphocytic leukemia and mantle cell lymphoma in combination with Pharmacyclics' Imbruvica delivered stellar results in the early going. Still, justifying a $400 million valuation based on the results of a single phase 1 study and the idea that it has two additional phase 1's under way might be a bit of a stretch. It admittedly licensed the IRAK4 program for a small sum (just 125,000 shares), so the deal itself looks promising on paper. The big question going forward is whether or not TG Therapeutics can justify its valuation with clinical follow-through over the next couple of years.

TG Therapeutics may have soared today, but keeping pace with this top stock over the long haul might prove impossible! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information